At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 5, 2026 at 07:00 ET
The primary news is the completion of statistical analyses from the failed Phase 3 LEVEL trial, yielding a predictive enrichment strategy being applied to the amended LEVEL-2 protocol, and a granted Type C meeting with the FDA. Cash runway extended through fiscal 2028.
- Cash and cash equivalents of $113.7M as of September 30, 2026; cash runway through fiscal 2028
- Phase 3 LEVEL trial did not meet primary endpoint; post hoc analysis identified enrichment criteria for LEVEL-2
- LEVEL-2 enrollment temporarily paused for protocol amendment to enrich for more symptomatic patients
- FDA granted a Type C meeting to discuss overall development of levosimendan in PH-HFpEF
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access